Vpriv Global Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The vpriv market research report is one of a series of new reports that provides vpriv market statistics, including the vpriv industry global market size, regional shares, competitors with the vpriv market share, detailed vpriv market segments, market trends, and opportunities, and any further data you may need to thrive in the vpriv industry. This vpriv market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The growth in the forecast period can be attributed to the increasing prevalence of rare diseases, the increasing number of products being approved, the increasing prevalence of genetic disorders, the rising demand for effective treatment options, and the growing awareness of rare genetic diseases. Major trends in the forecast period include growing focus on personalized medicine, increased adoption of patient-centric healthcare models, advancements in biologic manufacturing processes, the emergence of biosimilars, and increasing focus on sustainability in biologic drug production.

The increasing healthcare spending is expected to drive the growth of the Vpriv market in the future. This trend is fueled by factors such as aging populations, medical advancements, and the rising prevalence of chronic and rare diseases. As healthcare spending increases, it broadens access to advanced enzyme replacement therapies, making treatments such as Vpriv more affordable and accessible for patients with Gaucher disease type 1. It also supports investments in diagnostic and healthcare infrastructure, which are critical for addressing rare diseases. For example, in December 2023, the Centers for Medicare & Medicaid Services reported that U.S. healthcare spending grew by 4.1% in 2022, reaching $4.5 trillion, an increase from 3.2% in 2021. This rise in healthcare expenditure is contributing to the growth of the Vpriv market.

The growing acceptance of biologics is also expected to drive the Vpriv market in the coming years. Biologics are medical treatments derived from living organisms, such as proteins, vaccines, and gene therapies, and are used to address a range of diseases. Their increased acceptance is due to their effectiveness in treating complex, chronic, and rare diseases with more targeted, personalized approaches. Vpriv fits into this trend by offering an enzyme replacement therapy designed specifically for Gaucher disease type 1, showcasing the role of biologics in treating genetic disorders. For instance, by the end of 2022, the U.S. Food and Drug Administration had approved 40 biosimilars, with 27 of them available in the U.S., reflecting the growing embrace of biologic treatments. This shift towards biologics is fueling the expansion of the Vpriv market.

The rise of personalized medicine is another factor driving the growth of the Vpriv market. Personalized medicine tailors treatments based on an individual’s genetic makeup, lifestyle, and health conditions, allowing for more precise and effective interventions. This approach is gaining momentum thanks to advancements in genomics and the ability to better target diseases based on genetic and biomarker profiles. Vpriv aligns with personalized medicine by providing a targeted enzyme replacement therapy tailored to the needs of individuals with Gaucher disease. In February 2023, the Personalized Medicine Coalition reported that in 2022, 12 personalized medicines were approved, accounting for 34% of all new drug approvals. This growth in personalized treatments is contributing to the expansion of the Vpriv market.

The key company operating in the vpriv market is Takeda Pharmaceutical Company Limited

North America was the largest region in the vpriv market in 2024. The regions covered in vpriv report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the vpriv market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Vpriv (velaglucerase alfa) is a recombinant enzyme replacement therapy designed for the long-term treatment of Gaucher disease type 1, a rare genetic disorder caused by a deficiency of the enzyme glucocerebrosidase. It works by replacing the missing or deficient enzyme, helping to reduce the accumulation of fatty substances and alleviate the symptoms associated with the disease.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The main indications for Vpriv are type 1 Gaucher disease and type 3 Gaucher disease. Type 1 Gaucher disease is a rare genetic condition caused by a deficiency in glucocerebrosidase, the enzyme responsible for breaking down a fatty substance called glucocerebroside. Vpriv is distributed through various channels, including hospital pharmacies, retail pharmacies, online pharmacies, and specialty pharmacies, and is used by a range of patients, including adults, pediatric, and geriatric populations.

The vpriv market consists of sales of infusion equipment, supportive care medications, diagnostic tools, and patient monitoring tools. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.